MedImmune To Enhance Oncology Pipeline With Buyout Of Neighbor Amplimmune
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal brings AstraZeneca’s biologics subsidiary an anti-PD1 monoclonal antibody that could enter clinical trials this autumn. MedImmune will pay $225 million for the privately held biotech, with milestones of up to $275 million possible down the line.
You may also be interested in...
MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline
The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.
AstraZeneca Promises 10 New Drugs By 2020
CEO Pascal Soriot said the big pharma is on track to return to growth faster than anticipated, with 2017 revenues expected to be in line with 2013. A key driver of growth will be new drugs, many of which have been gained through deal-making and acquisitions.
AstraZeneca’s Promise To Investors: 10 New Drugs By 2020
CEO Pascal Soriot said the big pharma is on track to return to growth faster than anticipated, with 2017 revenues expected to be in line with 2013. A key driver of growth will be new drugs, many of which have been gained through deal-making and acquisitions.